Impact of thrombus aspiration conjugative with Anisodamine for the Prevention of No-reflow phenomenon following primary Percutaneous coronary intervention
Abstract
Objective:We sought to evaluate the combination therapy of thrombus aspiration plus anisodamine in prevention of No-reflowphenomenon during percutaneous coronary intervention.method:fromOctober 2009to June,143 consecutive patients with STEMI who received manualthrombus aspiration were involved in a
Double Center prospectively analysis.The patients were treated with anisodamine (1000fig/kg)plus Tirofiban (pg/kg) (Group A,n = Tirofiban and pg/kg alone (group B,n = respectively.The drugswere selectively injected into the infarct-related artery (IRA),Through the occlusion to the distal segment via the Thrombus ASPI
Theration catheter advanced MTO the IRA.Primary endpoints were postprocedural corrected thrombolysis in myocardial frame count (infarction).The proportion of complete c>70%)St-segment resolution (STR) myocardial blush Grade 2~3 (MBG) post PCI.Secondary endpoints included peak value of creatine kinase-MBTIMI flow grade;6-month outcome including left ventricular ejection fraction (LVEF),b16> as acardiac death target vascular revascularization,Re-infarction and their combination as major adverse cardiac events (MACE).result:Baseline characteristicswere not different between two groups.Compared to group B,Group A had①A lower corrected TIMI coronary flame count (_p<0.b20>,②ahigher proportionof completest-Segment Resolution (_P<0).
*PetroChinaHuabei Oilfield Company Science and technology project(no:2012-hb-g09-4
1North China Petroleum Administration General Hospital Heart II(Hebei Renqiu,062552
2North China Petroleum Administration General Hospital Maternity and Gynecology3Hebei Medical University Second HospitalDepartment of CardiologyCommunications author:Dongqiu,e-mail:dong12922@126.com
③a better myocardial blush 2-3grade ratio (_p = 0.),and④A lower peak creatine kinase-mb (_p0.()),
There is no differences in TIMI 3 flow grade between the two groups (P []B20>0.No differences were foundin
Cardiac Death,tvr,r^infarction,mace,between The two groups during 6-month follow-upOnly a improvement trend in groupeight(P0.05).Nevertheless, LVEF at6 month is higher in groupEight(P(0.01).Conclusion:
preventively intracoronary Administration of Anisodamine 1000 ug via thrombus aspiration catheter can improve myocardiAl reperfusion for acute STEMI with initial timi^2 treated with primary PCI.
References
chernow B,zaloga G P,mcfadden e,et al. hypocalcemia in critically ill patients [J].Crit Care med,1982,10:848-851.
desait K, CARLSON R W, Geheb M a.preva-
Lence and clinical implications of hypocalcemia in a cutely ill patients in a medical intensive care setting [].AMJ med,1988,84:209-214
Zivinj R ' Gooley tzager r a,t L hypocalcemia:a pervasive metabolic abnormality in the Criti-cally ill[j].Am Jkidneydis,2001,37:689-698.
vivien B,Langeron O,Morell E,et l Early hypocalcemia in severe trauma [J].Crit Care Med, 2005,33:1946-1952.
HOLOWAYCHUKMK,HANSENBD,Defran-cesco T c,et al. ionized hypocalcemia in critically ill D0gs[j].Jvetintern Med,2009,23:509-513.
ChuiHaibo,Liudawei,Yukejiang,, and so on.China Intensive care ward(ICU)Construction and Administration Guide[].China critical Medical Emergency Medicine,2006,18:387-388.
Bilevicius E,Dragosavac D,Dragosavac S,et al. Multiple organ failure in septic patients[j].BRAZJ Infectdis,2001,5:103-110.
FengShiyan.APACHEIIscore inICUapply[].Sichuan Medical
Learn,2003,24:1003-1004.
Dickerson R N, HENRY N Y, MILLER R L, et
Al. low serum total calcium concentration as a marker to low serum ionized calcium concentration in critically ills receiving specialized nutrition support[j].Nutr clinpract,2007,22:323-328.
Colucci W Molecular and cellular mechanisms of myocardial failure[j].AMJ cardiol,1997,80:15-25.
MALLAT Z,HENRY P,fressonnet R,et al. increased plasma concentrations of interleukin-18 in a cute coronary syndromes [J].Heart,2002,88:467-
Ms.,Chiyan,Hudan.exogenous albumin input toARDSMouseCRPand pre-calcitonin effects[].Journal of Qingdao University medicalCollege,
,45 (3) 235-237.
LEE C H, TSE h F. microvascular obstruction after percutaneous coronary intervention[j].Catheter Card-iovascinterv,2010,75:369-377.
eeckhout e,kern M J.The coronary no-reflow phenomenon:A review of mechanisms and therapies [J].Eur Heart J, 2001,22:729-739.
STONE G W,Maehara A,witzenbichler B,et al. intracoronary abciximab and aspiration thrombectomy in patients with large anterior in-farction:theinfuse-amirandomized trial [J].JA-ma,2012,307:817-1826.
FU X H,FAN W Z,GU XS,etal.Effectofintracoro-nary administration of Anisodamine on slow reflow phenomenon following primary percutaneous coronary inTervention in patients with acute myocardia 1 infarc-tion[j].Chin Med J,2007,120:1226-1231.
AMBROSIO G,weisman H F,mannisi J A,et al. progressive impairment of regional myocardial per-fusion after initial restoration of PostiscHemic Blood
L0w[j].Circulation,1989,80:1846-1861.
rochitte C E,LIMA J A,Bluemke D A,t al.
Magnitude and timecourse of microvascular obstruc-tion and tissue injury after acute myocardial infarction [J].Circulation,1998,98:1006-1014.
rezkalla S H,kloner R A. Coronary ncrreflow phenomenon:From theExperimental Laboratory to the cardiac catheterization laboratory[j].Catheter cardio-vasc interv,2008,72;950-957.
WeiYong,FuXianghua,Liu,, and so on.Intra-coronary injectionof Anisodamineeffect of on the slow-flow phenomenon of acute myocardial infarction after interventional therapy[].Journal of Clinical Cardiovascular disease,2006,22 (1):1-.
lepper W,sieswerda G T,vanoverschel-
DE J L,et al. Predictive value of markers of Myocardi-al reperfusion in acute myocardial for infarctionLow-up left ventricular function[J].Am J cardiol,
,:1358-1363.
(Draft date:013-02-19
Copyright (c) 2013 Zhao yujun
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution-Noncommercial 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear. With this license, the authors hold the copyright without restrictions and are allowed to retain publishing rights without restrictions as long as this journal is the original publisher of the articles.
